Bristol-Myers Squibb Company
BMY
$45.94
$0.150.33%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.77% | 0.56% | -5.60% | 7.54% | 8.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.77% | 0.56% | -5.60% | 7.54% | 8.44% |
| Cost of Revenue | 15.97% | 12.96% | 3.71% | 18.66% | 14.70% |
| Gross Profit | -1.39% | -3.43% | -8.62% | 4.10% | 6.61% |
| SG&A Expenses | -14.04% | -12.08% | -19.66% | -10.27% | 7.33% |
| Depreciation & Amortization | -65.46% | -65.65% | -64.79% | -25.68% | 6.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.73% | -15.27% | -20.00% | 0.21% | 9.40% |
| Operating Income | 75.60% | 59.05% | 54.82% | 43.29% | 4.42% |
| Income Before Tax | 85.80% | 37.79% | 125.80% | -89.55% | -21.57% |
| Income Tax Expenses | 99.35% | 215.58% | 29.85% | 212.50% | 127.09% |
| Earnings from Continuing Operations | 80.66% | -22.09% | 120.68% | -95.69% | -37.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 250.00% | 50.00% | -100.00% | -- | 33.33% |
| Net Income | 81.75% | -22.02% | 120.62% | -95.91% | -37.19% |
| EBIT | 75.60% | 59.05% | 54.82% | 43.29% | 4.42% |
| EBITDA | 1.38% | -1.16% | -4.87% | 5.57% | 5.79% |
| EPS Basic | 81.04% | -22.33% | 120.54% | -95.92% | -36.30% |
| Normalized Basic EPS | 69.70% | 58.80% | 49.52% | 3.90% | -4.16% |
| EPS Diluted | 80.87% | -22.78% | 120.37% | -95.91% | -35.80% |
| Normalized Diluted EPS | 69.71% | 58.72% | 48.86% | 3.80% | -3.98% |
| Average Basic Shares Outstanding | 0.39% | 0.39% | 0.40% | 0.10% | -1.41% |
| Average Diluted Shares Outstanding | 0.39% | 0.44% | 0.84% | 0.20% | -1.60% |
| Dividend Per Share | 3.33% | 3.33% | 3.33% | 3.33% | 5.26% |
| Payout Ratio | -0.43% | 0.33% | 6.03% | 24.70% | 0.63% |